Catalent, Inc. (CTLT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 105.99 |
| Open | 106.13 |
| Bid | 109.05 x 1000 |
| Ask | 109.07 x 1000 |
| Day's Range | 106.40 - 109.40 |
| 52 Week Range | 86.34 - 142.64 |
| Volume | |
| Avg. Volume | 1,269,540 |
| Market Cap | 18.683B |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | 34.35 |
| EPS (TTM) | 3.18 |
| Earnings Date | Jan 31, 2022 - Feb 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 138.15 |
- Business Wire
Catalent Announces New Operating Structure
SOMERSET, N.J., July 05, 2022--Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced changes to its operating structure and executive leadership team that went into effect July 1. This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenu
- Zacks
Catalent (CTLT) Expands Packaging Capabilities at Japan Facility
Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.
- Zacks
3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.
